201 related articles for article (PubMed ID: 23052034)
1. How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?
Kim ST; Park KH; Oh SC; Seo JH; Kim JS; Shin SW; Kim YH
Oncology; 2012; 83(6):354-60. PubMed ID: 23052034
[TBL] [Abstract][Full Text] [Related]
2. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer.
Yuge K; Miyajima A; Tanaka N; Shirotake S; Kosaka T; Kikuchi E; Oya M
Ann Surg Oncol; 2012 Nov; 19(12):3987-93. PubMed ID: 22872290
[TBL] [Abstract][Full Text] [Related]
4. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model.
Wang L; Cai SR; Zhang CH; He YL; Zhan WH; Wu H; Peng JJ
Chin Med J (Engl); 2008 Nov; 121(21):2167-71. PubMed ID: 19080179
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
Steely AM; Callas PW; Bertges DJ;
J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.
Nakai Y; Isayama H; Ijichi H; Sasaki T; Sasahira N; Hirano K; Kogure H; Kawakubo K; Yagioka H; Yashima Y; Mizuno S; Yamamoto K; Arizumi T; Togawa O; Matsubara S; Tsujino T; Tateishi K; Tada M; Omata M; Koike K
Br J Cancer; 2010 Nov; 103(11):1644-8. PubMed ID: 20978506
[TBL] [Abstract][Full Text] [Related]
7. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
8. Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC.
Miao L; Chen W; Zhou L; Wan H; Gao B; Feng Y
Sci Rep; 2016 Feb; 6():21359. PubMed ID: 26883083
[TBL] [Abstract][Full Text] [Related]
9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
11. Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution.
Onuigbo MA
Nephron Clin Pract; 2009; 113(2):c63-9, discussion c70. PubMed ID: 19602900
[TBL] [Abstract][Full Text] [Related]
12. Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients.
Raptis AE; Bacharaki D; Mazioti M; Marathias KP; Markakis KP; Raptis SA; Dimitriadis GD; Vlahakos DV
Exp Clin Endocrinol Diabetes; 2012 Jul; 120(7):416-9. PubMed ID: 22441720
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study.
Hernández D; Muriel A; Abraira V; Pérez G; Porrini E; Marrero D; Zamora J; González-Posada JM; Delgado P; Rufino M; Torres A
Nephrol Dial Transplant; 2012 Jan; 27(1):417-22. PubMed ID: 21622985
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma.
Chen YH; Huang CH; Lu HI; Chen CH; Huang WT; Hsieh MJ; Rau KM; Chang AY; Lin WC; Li SH
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1185-92. PubMed ID: 24961505
[TBL] [Abstract][Full Text] [Related]
15. Determinants and patterns of renin-angiotensin system inhibitors' prescription in the first year following kidney transplantation.
Thilly N; Bayat S; Alla F; Kessler M; Briançon S; Frimat L
Clin Transplant; 2008; 22(4):439-46. PubMed ID: 18318741
[TBL] [Abstract][Full Text] [Related]
16. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
17. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
19. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system.
Cotter J; Oliveira P; Cunha P; Polónia J
Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
